Project Grant R43AI177185
Award Date 9/15/23
Completion Date 8/31/25
Dollars Obligated $613K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- Project Grant Summary The University of North Carolina at Chapel Hill received a $427,625 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded April 1, 2026, with completion targeted for March 31, 2028. The project, titled "Coreceptor Therapy-Induced De-Differentiation of Autoreactive TFH," delivers preclinical research and development on a novel immunotherapy approach to...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Maryland, College Park $722,262 under the Allergy and Infectious Diseases Research program (CFDA 93.855) beginning February 19, 2026, with completion targeted for January 31, 2031. The project, "Guiding Innate Signaling in Skin with Microneedle Arrays to Promote Durable Antigen-Specific Tolerance During Autoimmunity," develops a novel therapeutic approach to address autoimmune diseases including...
- Federal Project Grant Award Summary Aleutian Therapeutics, Inc. received a $372,067 Project Grant award dated September 7, 2025, from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award supports the development of an immune-evasive stem cell line for Type 1 Diabetes (T1DM) regenerative therapy, with research to be conducted in California through August 31, 2026. This...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Leland Stanford Junior University a $5.58 million Project Grant (CFDA 93.847: Diabetes, Digestive, and Kidney Diseases Extramural Research) effective July 10, 2026, through June 30, 2029, to conduct research analyzing immune tolerance mechanisms in Type 1 Diabetes (T1D) patients receiving sequential B cell depletion and T cell costimulatory blockade therapy. The research leverages the...
- Grant Award Summary The Beckman Research Institute of The City of Hope received a $868,670 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective February 15, 2026, with a completion date of December 31, 2030. The award funds research into therapeutic approaches for Type 1 Diabetes (T1D) reversal through three integrated mechanisms: preservation of...
- Islex Therapeutics, LLC received a Phase I Small Business Innovation Research (SBIR) grant of $621,794 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award, dated August 1, 2025, with a completion date of July 31, 2026, supports preclinical development of a first-in-class, islet-targeted therapeutic antibody for Type 1 Diabetes (T1D). The company aims to...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant totaling $246,750 to The Trustees of Columbia University in the City of New York (Health Sciences Division) on May 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research on prolonged autoantigen expression via oral DNA vaccination to reestablish immune tolerance in Type 1 Diabetes (T1D) patients. The project will develop...
- Antiger Therapeutics Inc., a St. Louis-based biotech startup, received a $606,548 Project Grant awarded on August 11, 2025, by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant funds development of peptide-HLA-DQ8 biologics—innovative therapeutic candidates designed to selectively block pathogenic T cells in Type 1 Diabetes (T1D). The proposed product consists of functional multimers of insulin...
- Federal Project Grant Award Summary The University of Minnesota, through its Office of Sponsored Projects Administration, received a $4.5 million Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award, effective September 5, 2025, through August 31, 2028, funds research to develop engineered regulatory T cells (Tregs) as a therapeutic intervention for...
- Federal Project Grant Summary The University of Texas Southwestern Medical Center received a $799,693 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective June 1, 2026, through April 30, 2030. The award funds research to develop immune-checkpoint engineered pancreatic islet beta cells as a replacement therapy for Type 1 Diabetes (T1D). The...